The "Licensing Deals in Pharmaceuticals 2019-2025" has been added to ResearchAndMarkets.com's offering.

The report contains a comprehensive listing of licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report provides access to licensing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

The initial chapters offer an orientation into the dynamics of licensing dealmaking, introduced in Chapter 1. Chapter 2 covers the overall trends and merits of different types of deals, while Chapter 3 delves into deal structures. Chapter 4 reviews leading deals since 2019, with Chapter 5 listing the top 25 most active companies in licensing deals. Chapter 6 organizes the licensing deals by various categories such as company, therapy, technology, and industry, providing a detailed insight into these agreements.

Licensing Deals in Pharmaceuticals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

2.1. Introduction

2.2. Definition of licensing deal

2.3. Trends in licensing deals since 2019

2.3.1. Licensing dealmaking by year, 2019-2025

2.3.2. Licensing dealmaking by phase of development, 2019-2025

2.3.3. Licensing dealmaking by industry sector, 2019-2025

2.3.4. Licensing dealmaking by therapy area, 2019-2025

2.3.5. Licensing dealmaking by technology type, 2019-2025

2.3.6. Licensing dealmaking by most active company, 2019-2025

2.4. Reasons for entering into licensing partnering deals

2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

3.1. Introduction

3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

4.1. Introduction

4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

5.1. Introduction

5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

6.1. Introduction

6.2. Licensing deals with contracts 2019-2025

Deal directory

• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type

Companies Featured (Partial)

• Merus
• Sosei
• Northwestern University
• Viela Bio
• Beam Therapeutics
• Kinnate Biopharma
• Gritstone Bio
• Facet Biotech
• ArriVent Biopharma
• Syndax Pharmaceuticals
• GlycoMimetics
• Quadriga BioSciences
• Caris Life Sciences
• Emendo Bio
• Boston Scientific
• Analytical Biosciences
• Angion
• OrbiMed
• Apollomics
• CYTOVIA Therapeutics
• Luminex Corporation
• Enanta Pharmaceuticals
• Cirina
• Forge Therapeutics
• Arcturus Therapeutics
• Abarca Health
• Allogene Overland Biopharm
• Gilead Sciences
• Orum Therapeutics
• Haystack Oncology
• Density
• Eli Lilly and Company
• MD Anderson Cancer Center
• Newsoara Biopharma
• Zymergen
• Galecto
• A Roche Participations
• Arcturus
• Carina Biotech
• Angion Biomedica Corp
• SereneBiomics
• SIELC Technologies
• Precision Nanosystems
• Mitsubishi Tanabe Pharma
• Beigene
• Vincerx Pharma
• Focus Healthcare Partners
• Aeglea BioTherapeutics
• Antios Therapeutics
• NextCure

For more information about this report visit https://www.researchandmarkets.com/r/wph5hm

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250701444795/en/